Tesamorelin
Visceral abdominal fat in adults with HIV-associated lipodystrophy.
Research Summary
- Evidence
- Strong for its specific indication
- Primary research
- Randomized human trials in HIV-associated lipodystrophy.
- Research focus
- Visceral abdominal fat in adults with HIV-associated lipodystrophy.
- Mechanism
- GHRH analogue; stimulates pituitary GH release and raises IGF-1.
- Evidence limits
- Evidence for the approved population does not establish general fat-loss, muscle-building, bedtime, fasting, or cycling claims.
What tesamorelin is
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), the signal the body uses to tell the pituitary gland to release growth hormone. It works on the pituitary, so the body puts out its own growth hormone, and IGF-1 rises downstream as a result. It is sold as EGRIFTA SV and EGRIFTA WR. Its strongest human evidence is unusually specific: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
A common online story says tesamorelin burns stubborn belly fat, builds or preserves muscle, works best fasted before bed, and should be cycled or stacked with Ipamorelin. Some pieces of that have a biological rationale behind them. Several were never tested in the clinical trials.
Key safety point. The idea that tesamorelin “only releases your own GH, so high IGF-1 is harmless and more is better” is false. Tesamorelin can push IGF-1 well above the normal range for a person's age, can worsen blood sugar control, and has specific situations where it should not be used at all. The hormone coming from your own pituitary does not make heavy GH and IGF-1 exposure risk-free.
What the FDA approval covers
In the United States, EGRIFTA is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. That is a separate use from obesity treatment, cosmetic belly-fat loss, bodybuilding, anti-aging or general “GH optimisation.”
- Approved use: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.
- Not approved for: weight-loss management. The current label describes tesamorelin as weight-neutral.
Clinical formulations
| Formulation | Dose | What it is |
|---|---|---|
| Historical EGRIFTA (trial formulation) | 2 mg | The older formulation, used in the pivotal 26-week and 52-week visceral fat trials. |
| EGRIFTA SV | 1.4 mg | FDA data show it puts a similar amount of drug into the bloodstream as the older 2 mg formulation. |
| EGRIFTA WR | 1.28 mg | Also designed to deliver a similar amount of drug as the older 2 mg formulation. |
The formulation trap. These are three formulations of one drug, and they are not strength tiers. Milligrams cannot be compared unless you know which formulation produced the number. A vial labelled “tesamorelin 10 mg” from a research vendor is not automatically equivalent to EGRIFTA WR, EGRIFTA SV or the historical clinical formulation.
In short: it is approved for one thing, reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Weight loss, cosmetic fat loss, bodybuilding and anti-aging all sit outside that label, and the three milligram figures describe formulations rather than strengths.
Dosing evidence
Tesamorelin dosing is easy to misread because the formulation changed along the way. A milligram number tells you very little unless you also know which formulation produced it.
Dose at a glance
| Context | Dose | Details |
|---|---|---|
| Pivotal visceral fat trials | 2 mg daily | 26 weeks, extending to 52 weeks, using the historical EGRIFTA formulation. |
| HIV and liver fat trial | 2 mg daily | 6 to 12 months, also using the historical formulation. |
| EGRIFTA SV (current label) | 1.4 mg daily | The labelled SV dose, designed to deliver roughly the same drug exposure as the old 2 mg product. |
| EGRIFTA WR (current label) | 1.28 mg daily | The labelled WR dose, also designed to deliver roughly the same exposure as the old 2 mg product. |
| Community research-vial use | 1 to 2 mg daily | A common online cluster, often taken fasted and at night. Lower starting amounts and 5-on/2-off schedules also circulate. These community protocols have not been validated in trials, and research vials have no established formulation. |
All of these are given under the skin once a day. Because the formulations differ, three different milligram numbers (2 mg, 1.4 mg and 1.28 mg) were designed to put a similar amount of drug into the bloodstream.
Research-vial caution. The historical 2 mg dose is an efficacy anchor for the historical formulation. It does not show that 2 mg from an uncharacterised research vial produces the same exposure. Equivalence between the two has never been established.
Why 2 mg, 1.4 mg and 1.28 mg can all be “clinical”
The drug molecule is tesamorelin in every case. What changes is the formulation, and the formulation changes how much of each injection is absorbed. That is why the labelled milligram dose came down while the amount of drug reaching the bloodstream stayed about the same. The pivotal efficacy data come from the 2 mg historical formulation. EGRIFTA SV and WR are formulation changes built to match that exposure, so a lower milligram number does not mean a weaker dose.
Timing, fasting and cycles
Online protocols usually sound very precise. The clinical evidence is simpler: once-daily treatment is what was studied. Bedtime, fasting windows, weekend breaks and reset cycles were never established as requirements.
| Claim | Verdict | What the evidence shows |
|---|---|---|
| Once daily | Strongest support | The approved products and the pivotal trials all use one injection under the skin per day. The short time the drug spends in the blood does not create evidence for splitting the dose or redosing through the day. |
| Bedtime dosing | Plausible, unproven | Growth hormone rises naturally as you fall asleep, so bedtime dosing is physiologically coherent. No tesamorelin outcome trial shows better visceral fat loss from it. |
| Fasted dosing | Plausible, unproven | Blood sugar can influence how the pituitary responds, but no clinical trial established a required fasting window for tesamorelin to work. |
| Carbs “cancel” the dose | Overstated | Blood sugar can influence growth hormone physiology. That does not prove a meal makes tesamorelin ineffective. Glucose and GHRH interactions are timing-dependent [13]. |
| 5 days on, 2 days off | No trial basis | No evidence shows that weekend gaps improve receptor sensitivity, pituitary function, safety or visceral fat loss, or that they prevent tolerance. The human efficacy programmes dosed every day. |
| 8 to 12 week “cycle” | Outside the clinical model | The major visceral fat trials ran 26 to 52 weeks and the liver fat trial ran a full 12 months. Stopping was followed by visceral fat coming back. |
| Pre-workout or post-workout timing | No outcome basis | Claims that one timing burns fat while another builds muscle have never been tested in a tesamorelin outcome trial. |
Why the precise timing rules persist
- The physiology underneath is real. Growth hormone does pulse as you fall asleep [8], and glucose can blunt the pituitary response to a GHRH signal [9]. Both rules start from a true mechanism.
- Precision reads as expertise. “Fasted, 45 minutes before bed” sounds like it came from a protocol, and a specific instruction is easier to trust than a vague one.
- Nothing contradicts it. Nobody can feel the difference between dosing at 9pm and dosing at noon, so personal experience can never disprove the rule.
In short: the trials used 2 mg of the old formulation, the approved products use 1.4 mg (SV) and 1.28 mg (WR), and the online cluster is 1 to 2 mg. Once a day, every day, is what the approved products and every human trial used. Bedtime and fasting are physiologically sensible ideas that no outcome trial has tested, and weekend breaks and 8 to 12 week cycles have no trial basis.
Human trial evidence
Tesamorelin has considerably more human outcome data behind it than most compounds discussed in peptide communities. The results are strongest for visceral fat in HIV lipodystrophy, with narrower signals for liver fat and lean mass.
| Study population | Result | What was found |
|---|---|---|
| Pivotal HIV lipodystrophy trials | Strong positive | The historical 2 mg dose, injected under the skin daily for 26 weeks. Visceral fat fell by about 18% on average in one pivotal study and 14% in the other. Body weight barely moved [3,4]. |
| 52-week extension | Important | Staying on treatment held the visceral fat effect in place. Switching to placebo after 26 weeks let a substantial amount of that fat come back [4]. |
| HIV and fatty liver trial | Positive signal | The historical 2 mg dose daily for 12 months. Liver fat fell substantially compared with placebo in adults who had both HIV and fatty liver disease [7]. |
| Lean body mass | Real signal | The pivotal trials showed roughly 1.2 to 1.3 kg more lean body mass, which is a different measure from 1.2 to 1.3 kg of new skeletal muscle. |
| Healthy people who train | Not tested | No dedicated controlled trial shows that tesamorelin builds meaningful muscle or strips subcutaneous fat in healthy people who train. |
What visceral fat is
Visceral fat is the fat stored deep inside the abdomen, packed around and between the organs. It sits behind the wall of abdominal muscle, which is why you cannot get hold of it from the outside. It is a normal part of the body, and the question is only ever how much of it there is. The two fat layers are separated by muscle, which is why one can change while the other does not.
| Subcutaneous fat | Visceral fat | |
|---|---|---|
| Where it sits | Directly under the skin, all over the body. | Deeper, behind the abdominal muscle wall and in among the organs. |
| Can you pinch it | Yes. | No. If you can grab it, it is not visceral fat. |
| How it is measured | Calipers, a tape measure or a DEXA scan. | Needs a CT or MRI scan to measure properly. |
| What it does | Mostly a storage depot, relatively quiet. | More active, releasing fatty acids and inflammatory signals into the vein that runs straight to the liver. |
| Why it matters | Less strongly linked to metabolic risk. | A high amount is associated with insulin resistance, fatty liver and cardiovascular risk more strongly than the same amount of subcutaneous fat. |
| What you notice | Shapes the body in the mirror. | Pushes the abdominal wall outward from the inside, which is why a belly can be firm rather than soft. |
Does tesamorelin target belly fat?
Only in a narrow sense. “Belly fat” is too vague a phrase to be useful. The strongest trials measured visceral fat, the deep fat around the abdominal organs. They did not show a broad stripping of the surface layer you can pinch.
| Claim | Verdict | What the evidence shows |
|---|---|---|
| Reduces visceral fat | Strong in the approved population | Visceral fat fell about 18% (study 1) and 14% (study 2) on average at 26 weeks in the two pivotal studies. |
| Reduces subcutaneous belly fat | Little to no effect | Little to no meaningful reduction in the abdominal fat just under the skin across the pivotal work. |
| Body weight | Essentially neutral | Body weight was essentially unchanged in both studies, which is why tesamorelin is not a general weight-loss drug. |
| “18% visceral fat loss means 18% body-fat loss” | False | Visceral fat is one compartment. A change within it is not a change in whole-body fat percentage. |
| Injecting into the belly burns fat there | False | The injection site is a route of administration and does not produce spot reduction. The effect is systemic. |
| Love handles and lower belly | Not established | Those visible areas are mostly subcutaneous fat, the compartment that did not show the same signal. |
Why the claim persists: the starting point is a real result (visceral fat did fall 14% to 18%); the waist can visibly change, because when the deep fat shrinks the abdominal wall is pushed out less from the inside; and one phrase covers two tissues, with the injection going into the stomach area making local action feel obvious.
Does tesamorelin build or preserve muscle?
There is a real lean-mass signal, but the bodybuilding reading of it runs well ahead of the data. The pivotal HIV trials showed increased lean body mass. They were not muscle-growth trials in healthy people.
- Lean body mass: +1.2 to 1.3 kg, measured in the pivotal 26-week trials.
- Muscle CT analysis: an exploratory secondary analysis, limited to people who responded [6].
- Trials in healthy lifters: none. No dedicated muscle-growth trial has been run.
| Claim | Verdict | What the evidence shows |
|---|---|---|
| Lean mass equals muscle | Important caveat | A DEXA scan counts water and other non-fat tissue as lean mass. Drugs that work on the growth hormone axis can also cause fluid retention. |
| Water gain proves muscle gain | False | Swelling or a quick jump on the scale is not evidence of new muscle, and it can inflate a lean-mass reading. |
| “The recomp peptide” | Overstated | Losing visceral fat while lean mass ticks up can look like recomposition. It does not prove real muscle growth plus subcutaneous fat loss in healthy athletes. |
| Protects muscle on a GLP-1 | Unproven | No pivotal tesamorelin trial shows it is better than anything else at preventing the lean-mass loss that comes with GLP-1 drugs. |
“May support lean mass” is defensible. “Builds muscle” is not supported: lean mass counts water and organ tissue too, and the trial that would show the gain is muscle has never been run. The belief persists because the scan number really does go up, because growth hormone carries decades of bodybuilding association, and because early fluid retention makes muscles look fuller and the scale heavier.
Does tesamorelin reduce liver fat?
Yes, with direct human evidence, again in people with HIV. A randomised 12-month trial in adults with HIV and fatty liver disease used the historical 2 mg daily formulation under the skin [7].
- Liver-fat effect: about 37% average reduction compared with placebo.
- Reached under 5% liver fat: 35% of treated people, against 4% on placebo.
| Claim | Verdict | What the evidence shows |
|---|---|---|
| Reduces measured liver fat | Real human signal | Shown in adults who have HIV and fatty liver disease. |
| “Tesamorelin heals fatty liver” | Too broad | The result does not establish it as a treatment for fatty liver disease in people without HIV. |
| “It detoxes the liver” | False framing | Reducing fat in the liver in a defined population is not detoxification. |
| Prevents scarring or cirrhosis | Not established | The available evidence does not prove that long-term liver outcomes are prevented. |
| Prevents heart attacks | Not established | Visceral fat reduction and metabolic changes are stand-in measures. They are not evidence that heart attacks are prevented. |
Does visceral fat stay gone after a “cycle”?
No. The extension studies tested this directly: people who had responded to tesamorelin were switched to placebo, and a substantial amount of the visceral fat came back [4].
| Group (week 26 to week 52) | Change in visceral fat |
|---|---|
| Study 1, switched to placebo | +22% |
| Study 2, switched to placebo | +16% |
| Study 1, stayed on tesamorelin | 0% |
| Study 2, stayed on tesamorelin | -5% |
- Reversible effect: tesamorelin behaves like an ongoing drug effect, and the correction does not stay put once treatment stops.
- “A short cycle permanently fixes visceral fat” is false. After stopping, the fat came back.
- “A planned break protects the pituitary” has no human evidence. Continuous daily treatment was studied for up to 52 weeks, and no scheduled break has been shown to be necessary or useful.
- “Antibodies mean the receptor burned out” is not supported. Antibodies to tesamorelin did occur, but responses were not meaningfully different between people who had them and people who did not.
The cycle idea persists because fat lost through diet and training often stays off, because the reversal is invisible without a scan, and because the word “cycle” is borrowed from anabolic steroid culture, where the frame is “run a cycle and keep the gains.”
Stacking claims
Community protocols often add tesamorelin to another growth hormone secretagogue or to a GLP-1 drug. A logical mechanism is not the same thing as controlled outcome evidence. Tesamorelin earned its approval on its own, with no Ipamorelin, CJC-1295 or HGH involved.
| Combination | Verdict | What the evidence shows |
|---|---|---|
| Tesamorelin + Ipamorelin | Mechanistically plausible | Stimulating the GHRH receptor and the ghrelin receptor at the same time can amplify growth hormone release [10,11,14]. No controlled combination trial shows better visceral fat loss, muscle, sleep or safety. |
| Tesamorelin + CJC-1295 | Heavy overlap | Both push the same GHRH pathway [12]. A clinical benefit from stacking them has not been established. |
| Tesamorelin + HGH | Overlapping endpoint | Injected HGH bypasses the pituitary entirely. Running both can push GH and IGF-1 side effects higher, and no validated combined protocol exists. |
| Tesamorelin + a GLP-1 | Different pathways, untested | The theory is appetite and weight loss from one, visceral fat and lean-mass support from the other. Less redundant than the others, but not validated by any pivotal tesamorelin trial. |
The community theory is that a GHRH signal plus a ghrelin-receptor signal produces a stronger pulse of growth hormone, usually timed before sleep. That synergy is genuine: human studies show the combined signal produces a larger growth hormone pulse than either alone [10,11]. The stack inherits the mechanism but none of the clinical validation. A bigger hormone pulse sounds like a bigger result, though no outcome trial has checked, and vendors package and price these compounds together.
Safety and contraindications
Tesamorelin does more than “nudge growth hormone naturally.” It can raise IGF-1 enough that the FDA label calls for monitoring, and it can worsen blood sugar control and cause the fluid-retention symptoms familiar from growth hormone therapy [1].
| Issue | Status | What is established |
|---|---|---|
| IGF-1 rises | Important | At 26 weeks, 47% of treated patients were above the +2 standard deviation mark for their age and 36% were above +3. A reading that stays that high is a reason to reassess treatment. |
| “Higher IGF-1 is better” | False and risky | IGF-1 is not a score where a bigger number means a better result. |
| Blood sugar and diabetes | Real risk | HbA1c reached 6.5% or higher in 5% of tesamorelin patients, against 1% on placebo, across the clinical programme. |
| Fluid retention | Established | Swelling, joint pain, pain in the hands and feet, and carpal-tunnel-type symptoms can all occur. |
| Cancer | Contraindicated | Active cancer rules the drug out. A history of cancer calls for a careful weighing of risk and benefit. |
| Pituitary problems | Contraindicated | Tesamorelin needs a working pituitary to do anything. It cannot substitute for growth hormone in people whose pituitary has failed. |
| Injection-site and allergic reactions | Established | Redness, itching, pain, bruising, rash, hives and flushing have all been reported. |
The pituitary is involved, but growth hormone and IGF-1 downstream can still rise a long way. Monitoring IGF-1 and blood sugar matters far more than whether the injection went in exactly 45 minutes before bed.
Why the “natural release is risk-free” idea persists: a hormone the body already makes feels different from something injected, even though the resulting blood levels are what matter; people assume a gland under feedback control cannot overshoot, yet IGF-1 climbed past the normal range in nearly half of treated patients; and next to injected HGH, a secretagogue feels like the gentle option, so swelling and joint ache get read as signs it is working.
Evidence summary
| Claim | Verdict | Basis |
|---|---|---|
| Reduces visceral fat | Strong in HIV lipodystrophy | Large randomised trials show substantial visceral fat reduction. |
| A general weight-loss drug | No | Body weight was essentially neutral, and the FDA says it is not indicated for weight loss. |
| Burns visible belly fat | Not established | The pivotal data did not show the same reduction in the fat just under the skin. |
| Builds or preserves muscle | Signal, often overstated | Lean body mass increased. There is no dedicated muscle-growth trial in healthy people. |
| Reduces liver fat | Direct HIV signal | A randomised 12-month trial showed a meaningful reduction in liver fat. |
| Must be taken fasted at bedtime | Plausible, not proven | Physiology gives a rationale. Superiority has not been demonstrated in any outcome trial. |
| Needs 5 on, 2 off | No trial basis | The human efficacy programmes dosed every day. |
| Needs 8 to 12 week cycles | No reset evidence | Studies ran 26 to 52 weeks, and visceral fat came back after withdrawal. |
| 1.28 mg, 1.4 mg and 2 mg are directly comparable | No | Different formulations were designed to deliver similar exposure at different milligram doses. |
| Tesamorelin plus Ipamorelin is better | Mechanistic inference | No controlled combination trial establishes that it is. |
| Anti-aging or longer life | Not established | No tesamorelin trial demonstrates reversal of aging or a longer lifespan. |
| Higher IGF-1 is better | False | A reading that stays markedly high is a safety concern to act on. |
Conclusion
What is real: tesamorelin has unusually strong randomised human data for visceral fat reduction in HIV lipodystrophy, plus narrower signals for lean mass and liver fat.
What gets added online: cosmetic spot-fat claims, mandatory bedtime fasting, receptor-reset cycles, untested stacks, “natural GH is safe,” and anti-aging claims.
One claim holds up strongly: visceral fat reduction in HIV lipodystrophy. Liver fat and lean mass effects are real but smaller. Almost everything else is unproven or false. For the approved products, the labelled dose belongs to its formulation and is taken once daily, with IGF-1 and blood sugar monitored.
How the evidence ranks
| Level | Evidence |
|---|---|
| Highest confidence | FDA labelling plus randomised human trials in HIV lipodystrophy. |
| Useful but narrower | Exploratory muscle analyses and the HIV fatty-liver studies. |
| Mechanistic inference | Bedtime, fasting, and GHRH plus ghrelin-receptor synergy. |
| Community convention | 5-on/2-off, reset cycles, workout timing, research-vial dose ladders. |
A real clinical dose does not make an untested schedule clinical. A plausible mechanism does not make a stack proven. And “belly fat” does not mean all abdominal fat behaves the same way.
Sources
- U.S. FDA. EGRIFTA WR Prescribing Information, revised 2025. Current indication, 1.28 mg once-daily dose, pharmacokinetics, IGF-1, glucose and safety warnings.
- U.S. FDA. EGRIFTA SV Prescribing Information. 1.4 mg once-daily formulation and exposure comparison with historical EGRIFTA.
- Falutz J, et al. N Engl J Med. 2007. Randomized trial in adults with HIV and abdominal fat accumulation; historical 2 mg SC daily.
- Falutz J, et al. J Clin Endocrinol Metab. 2010. Pooled analysis of two Phase 3 tesamorelin trials with 26-week randomized phases and 26-week safety extensions; maintenance with continued therapy and VAT rebound after withdrawal.
- Stanley TL, et al. JAMA. 2014. Randomized trial of tesamorelin in adults with HIV; visceral and liver-fat outcomes.
- Adrian S, et al. J Frailty Aging. 2019. Exploratory CT analysis of muscle area and density in tesamorelin VAT responders.
- Stanley TL, et al. Lancet HIV. 2019. Randomized 12-month trial in adults with HIV and NAFLD; liver-fat reduction.
- Van Cauter E, Plat L. J Pediatr. 1996;128:S32-S37. PMID 8627466. Sleep-onset and slow-wave-sleep physiology supporting a bedtime rationale without proving tesamorelin outcome superiority.
- Masuda A, et al. J Clin Endocrinol Metab. 1985;60:523-526. PMID 3919046. Human experiment showing oral glucose can blunt the acute GH response to GHRH; supports a fasting rationale without establishing a tesamorelin-specific requirement.
- Bowers CY, et al. J Clin Endocrinol Metab. 1990;70:975-982. PMID 2108187. Human evidence that GHRP and GHRH can act synergistically to stimulate GH release.
- Hataya Y, et al. J Clin Endocrinol Metab. 2001;86:4552. PMID 11549707. Human evidence of synergistic GH release from ghrelin plus GHRH.
- Teichman SL, et al. J Clin Endocrinol Metab. 2006;91:799-805. PMID 16352683. Establishes CJC-1295 as a long-acting GHRH analog that increases GH and IGF-1.
- Valcavi R, et al. Clin Endocrinol (Oxf). 1990;32:539-543. PMID 2114240. Shows glucose and GHRH interactions are timing-dependent, supporting caution against the claim that carbohydrates simply cancel a dose.
- Raun K, et al. Eur J Endocrinol. 1998;139:552-561. PMID 9849822. Establishes Ipamorelin as a selective growth hormone secretagogue acting through the GHS/GHRP pathway; supports the mechanistic premise of Tesamorelin plus Ipamorelin, not clinical superiority.
Community sources
These record what people are being told online. They are not evidence that the claims are true.
- Reddit and peptide-community discussions covering 1 to 2 mg dosing, nighttime and fasted use, 5-on/2-off schedules, 8 to 16 week cycles, and stacking claims.
- Commercial peptide protocol pages covering Tesamorelin plus Ipamorelin, bedtime timing, pre and post-workout claims, and cycle structures.